Ltd has decided to launch a series of products as line extensions under the Corex
brand name, starting with the first launch in December 2016 and subsequent launches over the next year. At the same time, the company will discontinue the production of the current Corex cough syrup
formulation (a combination of codeine phosphate and chlorpheniramine maleate) in the country. Corex cough syrup
had recorded a sale of Rs 244.48 crores for the financial year ended March 31, 2016.
stands by the safety and efficacy of its current Corex cough syrup
formulation that has been duly approved by central and state regulators. As with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place,” said the company in a BSE filing today.
The decision was taken after Pfizer
undertook a comprehensive review of its respiratory offerings in order to better cover a broader range of indications through an expanded product portfolio. As a result of this review, the company decided to launch additional products while discontinuing the manufacture of certain SKUs.
“The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex cough syrup
formulation,” added Pfizer.